Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Theseus Pharmaceuticals, Inc. (THRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023"
07/13/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/25/2023 8-K Investor presentation
Docs: "Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST",
"TARGET ALL KEY MUTATIONS SELECTIVITY AND LONG-TERM TOLERABILITY 3"
05/11/2023 8-K Quarterly results
Docs: "Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results"
03/09/2023 8-K Quarterly results
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Legal notice and forward - looking statements 2 ©2023 Theseus Pharmaceuticals. Certain statements included in this presentation are not historical facts but are forward - looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward - looking statements generally are accompanied by words such as "believe ," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," “on track,” "predict," "potential," "seem," "seek," "future," "o utl ook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a st atement is not forward - looking. The...",
"Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL"
11/03/2022 8-K Quarterly results
10/19/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/15/2021 8-K Quarterly results
10/27/2021 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 25, 2021 Theseus Pharmaceuticals, Inc. Delaware 001-40869 83-0712806 245 Main Street Cambridge, Massachusetts 02142 400-9491 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy